The abstract is read at the publisher; the summary is JClub's.
Atirmociclib plus fulvestrant significantly improved investigator-assessed progression-free survival versus investigator’s choice therapy in HR-positive/HER2-negative advanced breast cancer, with median 9.4 vs 6.6 months.
- Why it matters: Patients with HR-positive/HER2-negative metastatic breast cancer who progress after prior CDK4/6 inhibitors need more effective options, and prior evidence for atirmociclib required randomized confirmation.
- What they did: In the open-label phase II FourLight-1 trial, 263 patients were randomized 1:1 to atirmociclib 300 mg twice daily plus fulvestrant or investigator’s choice (fulvestrant alone or everolimus plus exemestane), with PFS as the primary endpoint.
- The result: The stratified hazard ratio was 0.60 (95% CI 0.440–0.825; one-sided P = 0.0007), with consistent subgroup benefit; neutropenia (47.2%), leukopenia (33.6%), and diarrhea (28.0%) were common, and 6.4% discontinued due to TEAEs.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.